GARDEN GROVE, Calif., June 29, 2017 /PRNewswire/
-- HYCOR® Biomedical, a leading manufacturer of in vitro diagnostic products for allergy and autoimmune testing, announced today the addition of key personnel to the company's management team.
HYCOR has strengthened
its global team by adding several seasoned executives, including Eric Whitters, Ph. D. as Chief Operating Officer, Tommy Chiu as Vice President of Operations, Ulf Bladin, MBA as Vice President, General Manager for EMEA territory and Kim Walker, MS, FRAPS as Vice President of Regulatory, Quality, and Clinical Affairs.
"We're extremely pleased to add such highly talented and dedicated personnel to both our corporate management team in North America as well as group operations in Europe," said Richard Aderman, Chief Executive Officer at HYCOR. "These additions to our global leadership team bring a breadth of industry experience to help advance the company as we move toward regulatory approvals that will bring cutting edge technology to clinicians and laboratories worldwide."
The new HYCOR executives include:
- Eric Whitters, Ph. D., Chief Operating Officer, brings more than 22 years of research, development, quality, regulatory and operations experience from various sources including Fortune 500 organizations and niche diagnostic companies. Eric has vast experience delivering products to the U.S. and European marketplaces after leading development teams of more than eighty (80) assays for the IMMULITE®, TIGRIS®, PANTHER® and ECi® clinical systems. He has worked across a diverse spectrum of technologies including Point-of-Care (PoC), serology, immunochemistry, clinical chemistry & molecular diagnostics and within diverse disease states such as Allergy, Cardiac, Thyroid, Autoimmune, Infectious Disease, Sepsis and Anemia.
- Tommy Chiu, Vice President of Operations, brings a wealth of knowledge and experience in manufacturing operations refined over 34 years in the in vitro medical diagnostic industry with experience in international expansion in the United Kingdom and China. Tommy has worked in various capacities within manufacturing management and on the leadership team for Diagnostic Products Corporation®, which later became Siemens Healthcare Diagnostics®. He helped transition the company from a radioimmunoassay platform to the more innovative chemiluminescence methodology. In the start-up realm, Tommy helped Astute Medical Inc.® launch its immunoassay for assessing acute kidney injury (AKI) risk in the U.S. market.
- Ulf Bladin, Vice President, General Manager for EMEA territory, brings more than 25 years of diagnostics and pharmaceutical experience including sales and marketing, strategic positioning and several successful product launches at Merck Sharp & Dohme® and Pfizer®. He also played a key role at Phadia® as Vice President for Global Marketing, Scientific and Regulatory Affairs, and Corporate Communications. After the acquisition of Phadia by Thermo Fisher Scientific® in 2011, Ulf held the position as Vice President Commercial Operations Europe for the Immuno Diagnostic Division and member of the global leadership team.
- Kim Walker, Vice President of Regulatory, Quality and Clinical Affairs, brings more than 24 years of industry experience across several areas including clinical lab, blood banking, veterinary, biologics, pharmaceuticals, devices and IVDs. Prior to joining HYCOR, Kim ran her own consulting business for 11 years. She also worked for Beckman Coulter® as a Manager, Regulatory Affairs. Kim has participated on the CLSI Point of Care Testing, Quality Systems, and Process Improvement working groups. She has been a course developer and instructor for several graduate and undergraduate regulatory, quality, and clinical courses.
About HYCOR Biomedical Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC® and AUTOSTAT® brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.
IMMULITE® is a trademark of Siemens Healthcare Diagnostics, Inc. PANTHER® is a trademark of HologicECi® is a trademark of Ortho Clinical Diagnostics
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hycor-biomedical-announces-senior-level-appointments-to-management-team-300481578.html
SOURCE HYCOR Biomedical